From: Predicting response to neo-adjuvant chemotherapy and assessment of residual disease in breast cancer using contrast-enhanced spectral mammography: a combined qualitative and quantitative approach
Pathologic response
Complete responder
Incomplete responder
Count
%
RECIST 1.1 evaluation
CR
20/21
95.23%
1/60
1.7%
ICR
1/21
4.76%
59/60
98.3%
Combined response evaluation
95.23